vTv Therapeutics heads into its May 14 earnings release after posting Q1 results that landed well above expectations on both the top and bottom lines — a print that looks set to unwind the short-side positioning that built steadily through April and into this week.
The bear setup into the print was real. Short interest climbed 75% over the past month, reaching 3.5% of the free float, with the most aggressive leg of that build — a 44% jump — arriving in the final week alone. The ORTEX short score ticked up to 51.5 by May 12, rising from the low 40s at the start of the month, a clear signal that the skeptic trade was accelerating into the announcement. Borrow conditions remained comfortable, with cost to borrow running around 4.1% and availability loosening well off the tighter levels seen in mid-April — meaning new shorts faced no structural friction in establishing positions.
The fundamental debate centred on cadisegliatin, vTv's lead candidate targeting Type 1 diabetes. Bulls pointed to an unmet need in the GLP-1 era and a pipeline with platform optionality. Bears flagged the competitive density of the diabetes space, dependence on external partnership capital, and a regulatory path that remains far from certain. Six analysts carried Buy ratings heading into the print, with the most recent price targets ranging from $44 to $67 — all set between late 2025 and mid-March 2026 — placing the consensus mean at $53 against a closing price of $31.67. That gap was either opportunity or a valuation mirage, and the quarterly numbers are now forcing the answer. Q1 EPS came in at $1.65, crushing the -$0.10 estimate. Revenue hit $36.8M, more than $16M ahead of the $20M consensus — a blowout on both metrics that suggests the bear case was badly mispriced.
The ownership table adds an interesting wrinkle. MacAndrews & Forbes holds 12% of shares, making it the dominant anchor. Millennium Management disclosed a new position of 225,000 shares as recently as April 13, and JDRF T1D Fund and Breakthrough T1D each disclosed fresh stakes of 215,692 shares — specialist diabetes investors buying in just weeks before the print. Fidelity also added about 76,000 shares in the quarter. That cluster of informed, sector-focused buyers accumulating near the $30 level gives the bull case a credibility it may have lacked on paper alone.
The print's job was to test whether cadisegliatin's commercial momentum could justify a re-rating from a stock that had already shed 13% over the prior month. With a top-and-bottom-line blowout now on the tape, the question shifts to what the revenue line actually represents — milestone payments, royalties, or early product receipts — and whether it signals a durable inflection or a one-quarter event.
See the live data behind this article on ORTEX.
Open VTVT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
